CN104918960B - 改进的人类疱疹病毒免疫疗法 - Google Patents

改进的人类疱疹病毒免疫疗法 Download PDF

Info

Publication number
CN104918960B
CN104918960B CN201380065495.XA CN201380065495A CN104918960B CN 104918960 B CN104918960 B CN 104918960B CN 201380065495 A CN201380065495 A CN 201380065495A CN 104918960 B CN104918960 B CN 104918960B
Authority
CN
China
Prior art keywords
protein
cmv
cells
ctl
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380065495.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN104918960A (zh
Inventor
R·康纳
D·维贾延德拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
QIMR Berghofer Medical Research Institute
Original Assignee
Queensland Institute of Medical Research QIMR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012904604A external-priority patent/AU2012904604A0/en
Application filed by Queensland Institute of Medical Research QIMR filed Critical Queensland Institute of Medical Research QIMR
Priority to CN202410527083.3A priority Critical patent/CN118359733A/zh
Publication of CN104918960A publication Critical patent/CN104918960A/zh
Application granted granted Critical
Publication of CN104918960B publication Critical patent/CN104918960B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380065495.XA 2012-10-19 2013-10-21 改进的人类疱疹病毒免疫疗法 Active CN104918960B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410527083.3A CN118359733A (zh) 2012-10-19 2013-10-21 改进的人类疱疹病毒免疫疗法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2012904604A AU2012904604A0 (en) 2012-10-19 Improved human cytomegalovirus immunotherapy protein
AU2012904604 2012-10-19
PCT/AU2013/001216 WO2014059489A1 (en) 2012-10-19 2013-10-21 Improved human herpesvirus immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410527083.3A Division CN118359733A (zh) 2012-10-19 2013-10-21 改进的人类疱疹病毒免疫疗法

Publications (2)

Publication Number Publication Date
CN104918960A CN104918960A (zh) 2015-09-16
CN104918960B true CN104918960B (zh) 2024-06-14

Family

ID=50487350

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380065495.XA Active CN104918960B (zh) 2012-10-19 2013-10-21 改进的人类疱疹病毒免疫疗法
CN202410527083.3A Pending CN118359733A (zh) 2012-10-19 2013-10-21 改进的人类疱疹病毒免疫疗法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410527083.3A Pending CN118359733A (zh) 2012-10-19 2013-10-21 改进的人类疱疹病毒免疫疗法

Country Status (7)

Country Link
US (4) US9901632B2 (https=)
EP (3) EP2909238A4 (https=)
JP (4) JP2015533366A (https=)
CN (2) CN104918960B (https=)
AU (2) AU2013332272B2 (https=)
CA (1) CA2889064A1 (https=)
WO (1) WO2014059489A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2909238A4 (en) 2012-10-19 2016-11-30 Queensland Inst Med Res IMPROVED IMMUNOTHERAPY AGAINST HUMAN HERPESVIRUS
NZ736675A (en) * 2015-05-12 2023-03-31 Memorial Sloan Kettering Cancer Center Methods of treating epstein-barr virus-associated lymphoproliferative disorders by t cell therapy
CN105030047A (zh) * 2015-08-31 2015-11-11 捷赛厨电（北京）科技有限公司 可控制油烟的炒锅
CN110234358A (zh) * 2016-07-18 2019-09-13 昆士兰医学研究所理事会 多病毒特异性的t细胞免疫疗法
BR112020012361A2 (pt) * 2017-12-20 2020-11-24 Glaxosmithkline Biologicals S.A. constructos de antígeno do vírus epstein-barr
AU2019268545A1 (en) * 2018-05-18 2020-12-10 The Council Of The Queensland Institute Of Medical Research Adoptive T-cell therapy for CMV infection and CMV-associated diseases
US20210301255A1 (en) 2018-09-10 2021-09-30 Atara Biotherapeutics, Inc. Methods for expanding antigen-specific car-t cells, compositions and uses related thereto
US11810904B2 (en) 2020-02-24 2023-11-07 PlayNitride Display Co., Ltd. Micro light emitting diode structure and manufacturing method thereof and micro light emitting diode device
CN111394376B (zh) * 2020-03-30 2023-04-28 济宁医学院 一种融合基因bfna、重组腺病毒及其制备方法和应用
JP2023526766A (ja) * 2020-04-28 2023-06-23 ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ ヒトサイトメガロウイルスポリエピトープワクチン組成物
CN113621070A (zh) 2020-05-06 2021-11-09 华夏英泰（北京）生物技术有限公司 一种t细胞抗原受体、其多聚体复合物及其制备方法和应用
AU2021356478A1 (en) * 2020-10-07 2023-06-01 The Council Of The Queensland Institute Of Medical Research Herpesvirus polyepitope vaccines

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005007689A1 (en) * 2003-07-11 2005-01-27 Alphavax, Inc. Alphavirus-based cytomegalovirus vaccines
WO2006056027A1 (en) * 2004-11-29 2006-06-01 The Council Of The Queensland Institute Of Medical Research Human cytomegalovirus immunotherapy

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPM446594A0 (en) 1994-03-16 1994-04-14 Csl Limited Cytotoxic t-cell epitopes identified within epstein-barr virus
US6703024B2 (en) * 1996-05-24 2004-03-09 The Council Of The Queensland Institute Of Medical Research EBV CTL epitopes
AUPO007396A0 (en) 1996-05-24 1996-06-20 Csl Limited Ebv ctl epitopes
AUPO784197A0 (en) 1997-07-10 1997-08-07 Csl Limited Treatment of nasopharyngeal carcinoma
US7005131B1 (en) * 1999-08-13 2006-02-28 The Rockefeller University Protective antigen of Epstein Barr Virus
EP1242108B1 (en) 1999-12-28 2007-07-11 Pharmexa Inc. Optimized minigenes and peptides encoded thereby
AUPR593101A0 (en) * 2001-06-26 2001-07-19 Council Of The Queensland Institute Of Medical Research, The Cytomegalovirus t cell epitopes
AU2002950183A0 (en) * 2002-07-12 2002-09-12 The Council Of The Queensland Institute Of Medical Research Expression of hydrophobic proteins
CA2500955A1 (en) 2002-10-03 2004-04-15 Genencor International, Inc. Optimized multi-epitope constructs and uses thereof
US20070048329A1 (en) 2002-11-07 2007-03-01 Rajiv Khanna Epstein barr virus peptide epitopes, polyepitopes and delivery system therefor
CA2611721C (en) 2005-06-30 2014-04-22 Eisai Co., Ltd. Compounds for preparing immunological adjuvant
EP2313503A4 (en) * 2008-08-01 2014-01-08 Merck Sharp & Dohme Variant HCMV-PP65, IE1 and IE2 polynucleotides, and uses thereof
WO2010114628A2 (en) * 2009-04-03 2010-10-07 Duke University Formulation for inducing broadly reactive neutralizing anti-hiv antibodies
US20120052088A1 (en) * 2009-04-30 2012-03-01 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
JP6294076B2 (ja) * 2011-01-06 2018-03-14 ビオノール イミュノ エーエスＢｉｏｎｏｒ Ｉｍｍｕｎｏ Ａｓ 多量体ペプチド
EP2909238A4 (en) 2012-10-19 2016-11-30 Queensland Inst Med Res IMPROVED IMMUNOTHERAPY AGAINST HUMAN HERPESVIRUS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005007689A1 (en) * 2003-07-11 2005-01-27 Alphavax, Inc. Alphavirus-based cytomegalovirus vaccines
WO2006056027A1 (en) * 2004-11-29 2006-06-01 The Council Of The Queensland Institute Of Medical Research Human cytomegalovirus immunotherapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Julie S. Nielsen等.An in vitro -transcribed-mRNA polyepitope construct encoding 32 distinct HLA class I-restricted epitopes from CMV, EBV, and Influenza for use as a functional control in human immune monitoring studies.《Journal of Immunological Methods》.2010,第149-156页. *

Also Published As

Publication number Publication date
JP2021036882A (ja) 2021-03-11
JP7110302B2 (ja) 2022-08-01
US9901632B2 (en) 2018-02-27
EP2909238A4 (en) 2016-11-30
US11896665B2 (en) 2024-02-13
JP2018075034A (ja) 2018-05-17
CA2889064A1 (en) 2014-04-24
JP2019030331A (ja) 2019-02-28
US20210299248A1 (en) 2021-09-30
US20240156953A1 (en) 2024-05-16
CN104918960A (zh) 2015-09-16
CN118359733A (zh) 2024-07-19
US20180207261A1 (en) 2018-07-26
EP2909238A1 (en) 2015-08-26
US11065329B2 (en) 2021-07-20
US20150273051A1 (en) 2015-10-01
EP3872097A1 (en) 2021-09-01
JP6846396B2 (ja) 2021-03-24
AU2013332272A1 (en) 2015-05-14
JP2015533366A (ja) 2015-11-24
EP3466980A3 (en) 2019-05-01
EP3466980A2 (en) 2019-04-10
AU2013332272B2 (en) 2018-12-20
WO2014059489A1 (en) 2014-04-24
AU2018274961A1 (en) 2019-01-03

Similar Documents

Publication Publication Date Title
CN104918960B (zh) 改进的人类疱疹病毒免疫疗法
AU2006200654B2 (en) Inducing cellular immune responses to human papilloma virus using peptide and nucleic acid compositions
DK1409527T3 (en) NOVEL cytotoxic T cell epitopes AND polyepitopes human cytomegalovirus (HCMV), compositions comprising them and diagnostic and prophylactic and therapeutic uses thereof
CA2552508A1 (en) Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
WO2006056027A1 (en) Human cytomegalovirus immunotherapy
US20070048329A1 (en) Epstein barr virus peptide epitopes, polyepitopes and delivery system therefor
Clinton et al. EEHV1A glycoprotein B subunit vaccine elicits humoral and cell-mediated immune responses in mice
Liu et al. Immunotherapy of Epstein-Barr virus associated malignancies using mycobacterial HSP70 and LMP2A356–364 epitope fusion protein
HK40057947A (en) Improved human herpesvirus immunotherapy
HK40006634A (en) Improved human herpesvirus immunotherapy
US20230173061A1 (en) Human cytomegalovirus polyepitope vaccine composition
US20070237790A1 (en) Identification of gene sequences and proteins involved in vaccinia virus dominant T cell epitopes
Santana et al. Bicistronic DNA Vaccines Simultaneously Encoding HIV

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment

Free format text: NEW EXPIRY DATE: 20341202